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LETTER TO THE EDITOR
Myelodysplastic syndromes (MDS) are a heterogeneous group of myeloid neoplasms associated with aberrant myeloid differentiation and ineffective hematopoiesis leading to cytopenias. A considerable amount of more than 20% of MDS patients experience transformation into secondary acute myeloid leukemia (s-AML). To date, data on the comprehensive molecular and cytogenetic basis of leukemic transformation into AML are rare and there is a compelling need to identify the specific molecular events potentially driving this process. Therefore, we analyzed a cohort of 38 patients with paired samples from MDS and s-AML time points and applied cytogenetics and a 33-gene pan-myeloid panel for comparison of mutation frequencies and patterns within these two groups. We further compared these in relation to a large cohort of 494 MDS patients, showing no transformation to s-AML. We identified mutations in genes of the cellular signal transduction to drive transformation, and several MDS typical mutations to predispose to s-AML transformation. In addition, karyotype evolution was detected in more than one third of patients underlining its important impact on s-AML transformation.
We identified 38 patients (11 female, 27 male) that were analyzed in our laboratory by cytomorphology and cytogenetics both at diagnosis of MDS and later at progression to s-AML. The median age at diagnosis of MDS was 71 years (range 59-86 years). The median time to progression was 18 months (range: 2 -72 months Cytogenetically, a total of 14/38 (37%) MDS and 22/38 (58%) s-AML samples presented an aberrant karyotype and 13 patients (34%) gained chromosome abnormalities during progression to s-AML. One of these patients showed in parallel clonal evolution in one cytogenetic clone but lost another cytogenetic clone completely. These findings again confirm that cytogenetic evolution in MDS has been associated with progression to AML.
2;3
The most frequently occurring recurrent abnormality at MDS stage was trisomy 8 (+8; n=5), followed by del(5q) and del(20q) both in two patients each. While in s-AML patients a +8 occurred in four additional patients amounting to nine cases in total, del(5q) and del(20q)
were rarely gained at s-AML (one case with del(5q)). Although a normal karyotype was more often found at the MDS stage compared to the s-AML transformed samples, this difference was not statistically significant. Illustration of the cytogenetic patterns at both MDS and s-AML states is shown in figure 1 as well in supplemental table S1.
We next analyzed the distribution of molecular mutations in patients at MDS and s-AML stages. All samples presented at least one mutation in both MDS and s-AML disease states.
The most frequently mutated genes were largely matching for MDS and s-AML and showed the following mutation frequencies, respectively: SRSF2 (47% MDS; 47% s-AML), RUNX1 (37%; 40%), ASXL1 (37%; 42%), TET2 (34%; 34%), and SF3B1 (24%; 24% Comparing the frequencies of mutational acquisition in cases with and without karyotype alteration at leukemia transformation revealed that only eight of the 26 cases that acquired mutations showed also gains of cytogenetic aberrations, while 18 cases remained cytogenetically stable. Interestingly, none of the patients that acquired a mutation in NRAS or FLT3 (n=12) presented with karyotype transformation, and only three patients acquiring a KRAS mutation showed also cytogenetic transformation (figure 2).
We further compared the MDS data set of the presented study to our results of an independent previously published MDS cohort. 11 WHO diagnosis categories were matched between cohorts, and cases showing transformation to s-AML were excluded. Cases with follow-up less than 18 months (the median time to transformation of the MDS/s-AML cohort)
were also excluded, resulting in a final cohort of 494 patients. A comparable frequency of patients showed aberrant karyotypes at their MDS stage (37% vs 29% in the published control cohort, respectively). However, trisomy 8 appeared more frequently in MDS patients with progression to s-AML than in the control MDS cohort (13% vs 3%; p=0.015) (figure 3).
We further compared the mutation frequencies between these two cohorts, and found that in MDS cases transforming to s-AML the following mutations were more frequent than in the p<0.001), and SRSF2 (47% vs 14%; p<0.001). Mutations in these genes might thus predispose to s-AML progression (figure 3). To further validate our findings we then focused on the patients previously excluded from the control cohort that also transformed to s-AML (n=78) and analyzed the differences in cytogenetics and mutation frequencies to the MDS cases of the present MDS/s-AML cohort. Both MDS to s-AML cohorts showed comparable frequencies of aberrations and mutations, again supporting that the previous findings are specific for MDS cases transforming to s-AML (supplemental figure S3 ). Previous studies on MDS patients showed that mutations in ASXL1, ETV6, EZH2, IDH2, RUNX1, and TP53 are predictors of poor overall survival in MDS patients independent of other established risk factors. [11] [12] [13] Furthermore the splicing machinery is one of the most frequently affected pathways in MDS, 14 and mutations in SRSF2 have been shown to be independently associated with a negative prognosis for overall survival and AML transformation. 15 Recently, 5 several of these gene mutations were identified as specific for s-AML in comparison to de novo AML underlining their function in dysplastic differentiation since they occur already at MDS stage. 9 But these gene mutations have to be differentiated clearly from the mutations exclusively found in s-AML status.
In conclusion, our data suggests that different underlying molecular mechanisms drive the progression from MDS to s-AML. On the one hand, karyotype evolution has an important impact on s-AML transformation. On the other hand, several mutations including those in ASXL1, ETV6, GATA2, IDH2, NRAS, RUNX1, and SRSF2 predispose to transformation to s-AML. However, mutations in signal transduction genes (FLT3, KRAS, and NRAS) seem to drive the progression from MDS to s-AML quicker if mutated at a specific time point and should therefore be considered as prognostically informative during disease course.
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Patient cohorts
A total of 38 patients were analyzed both at diagnosis of MDS and later at progression to s- and MDS with isolated 5q deletion (n=1).
For comparison a subgroup of the MDS cohort previously published in Haferlach et al. 2 
was taken. From this cohort, patients showing a transformation to s-AML were excluded (n=78)
and taken as separate control cohort. Since the median time to transformation was 18 months in the MDS/s-AML cohort, all cases with follow-up less than 18 months were also excluded from this control cohort. The cohort was matched to WHO diagnosis of the present MDS/s-AML cohort, resulting in the final MDS control cohort of 494 patients.
All patients gave their written informed consent for scientific evaluations. The study design adhered to the tenets of the Declaration of Helsinki and was approved by our institutional review board before its initiation.
Cytomorphology
In all cases bone marrow smears underwent May Giemsa Gruenwald staining. For cytomorphology, 200 nucleated cells were counted in the bone marrow. Cytochemistry was performed for myeloperoxidase (MPO) and non-specific esterase (NSE), and iron staining was done for detection of ring sideroblasts in cases with increased erythropoiesis or anemia.
Classification of the disease entities and dysplasia was rated according to WHO criteria. 
Cytogenetics and fluorescence in situ hybridization (FISH)
Chromosome banding analysis was performed in all cases after short-term culture.
Karyotypes were analyzed after G-banding and described according to the International System for Human Cytogenetic Nomenclature. 3 Interphase FISH was applied with probes for the centromeric region of chromosome 8 (CEP8 DNA probe kit, ABBOTT, Wiesbaden, Germany). All karyoytpes are given in table S1. 46,XY.ish del(4)(q24q24)(TET2-) [11] 48,XY,+8,+20.ish del(4)(q24q24)(TET2-) [1] 49,XY,+5,+8,+20.ish del(4)(q24q24)(TET2-) [2] 50,XY,+5,+8,+15,+20.ish del(4)(q24q24)(TET2-) [ 
Isolation of nucleic acid
DNA or RNA from fresh bone marrow cells was isolated after Ficoll separation of mononucleated cells. DNA was isolated using the DSP DNA Midi Kit and the QIAsymphony instrument (Qiagen, Hilden, Germany). RNA was isolated using the MagNa Pure LC system with the corresponding mRNA HS Kit (Roche Applied Science, Mannheim, Germany). RNA was reverse transcribed with 500 U SuperScript II Reverse Transcriptase enzyme (Invitrogen, Carlsbad, CA) in a 50 µl reaction using random hexamers as primers.
Targeted library preparation and next generation sequencing
The Build 510 (JSI Medical Systems, Kippenheim, Germany) for alignment and variant calling.
If a mutation was detected in any s-AML sample, that was not present during MDS stage, the sequence was manually analyzed and sequenced by using the 454 platform to ensure that no mutations with low mutation load were missed.
Next generation sequencing of RUNX1 and ZRSR2
Next generation deep-sequencing of the RUNX1 and ZRSR2 gene was performed using the 454 GS FLX amplicon chemistry (Roche Applied Science) as previously described. MiSeq v3 (600-cycles) reagent cartridges (Illumina) were used to sequence libraries with paired-end (2 x 301). All steps were performed according to the instructions of the manufacturers.
PCR for detection of MLL-PTD and FLT3-ITD
MLL-PTD was analyzed with a quantitative PCR assay, FLT3-ITD was analyzed by gene scan, both described methodically previously. 5;6 Detection limit for FLT3-ITD was 5%.
Statistical analyses
Dichotomous variables were compared between different groups using the χ 
Analyses of mutational loads of mutations at MDS and s-AML stages -clonal evolution
Next generation sequencing allows to investigate variant allele frequencies. In the total cohort of 38 paired samples (n=76) the allele frequencies were analyzed. However, the major changes between MDS and s-AML stages were gain or loss of mutation. The persisting mutations remained quite stable with only single exceptions. The allele frequencies for all patients and genes that were either at MDS or s-AML or both stages mutated are given in 
Comparison of MDS/s-AML cases at MDS stage with independent MDS/s-AML control cohort
To validate our findings, we defined cases of the previously published well characterized MDS cohort, 2 that showed transformation to s-AML (n=78) and compared these MDS cases with the MDS cases of the present cohort, regarding cytogenetics and molecular mutations.
There were no significant differences in mutation frequencies. The associations as well the numbers of cases with mutations are given in figure S3 . These results validate that the detected increased mutation frequencies in ASXL1, CBL, GATA2, IDH2, NRAS, RUNX1, and SRSF2 relative to MDS cases without transformation, impact the disease progression to s-AML. 
